Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Report Store
UsernamePublicRestriction
Tags:
Hong Kong Regulation Regenerative Medicine

Hong Kong Looks To EU For New Advanced Therapy Rules

  • News

Executive Summary

Hong Kong is consulting on proposals to include advanced therapies in its regulatory framework for pharmaceuticals.

You may also be interested in...



Scrutiny In Store For Hong Kong’s First Advanced Therapy Rules

Requirements for advanced therapies in Hong Kong are being modeled on the EU regulatory regime.

Scrutiny In Store For Hong Kong’s First Advanced Therapy Rules

Requirements for advanced therapies in Hong Kong are being modeled on the EU regulatory regime.

Migraine & Hepatitis B Prevention Products Among New EU Filings

The latest list of marketing authorization applications under review by the European Medicines Agency includes filings for eight new products.

Table

View full table

Topics

Tags:
Hong Kong Regulation Regenerative Medicine
UsernamePublicRestriction

Register

LL1126230

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By